SEC Filing Analysis: Natera, Inc. (NTRA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: President of Clinical Diagnostics disposed of 18,160 shares totaling ~$5.92M primarily for tax withholding on RSU vesting and via a 10b5-1 plan.
• Market Impact: Immaterial impact given the transaction represents less than 0.013% of Natera's $47.18B market cap.

Company Information

Field	Value
Company	Natera, Inc.
Ticker Symbol	NTRA
CIK	0001604821
Industry	Medical Laboratories

Insider Information

Field	Value
Name	Solomon Moshkevich
CIK	0002010019
Title/Position	President, Clinical Diagnostics
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-01 / 2026-09-02
Transaction Code	S (Open Market Sale)
Security Type	Common Stock
Shares Involved	18,160
Price Per Share	~$325.80 (Weighted Average)
Total Value	$5,916,499.78
Shares Owned After	110,859
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$5,916,499.78
% of Market Cap	0.0125%
Shares Transacted	18,160
% of Shares Outstanding	0.0127%
Post-Transaction Ownership	110,859 shares (0.0774% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: In the context of Natera's $47.18B market capitalization, a $5.92M sale represents a routine executive disposition.
• Ownership Concentration: Moshkevich maintains direct ownership of 110,859 shares (0.0774% of outstanding shares).
• Dilution Impact: None; transactions were open-market sales rather than newly issued shares.
• Transaction Significance: Low significance under standard threshold criteria (<0.1% market cap and <0.1% shares outstanding).

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Dispositions were pre-scheduled via Rule 10b5-1 plans and tax-related withholding instructions, presenting no discretionary negative directional bias.

Volume & Sentiment

• Expected Volume Impact: Negligible
• Sentiment Indicator: Neutral

Additional Context

Transaction Notes

• Special Circumstances: 3,000 shares sold on 2026-09-01 were executed under a Rule 10b5-1 plan adopted on November 26, 2024. The remaining 15,160 shares sold on 2026-09-02 were strictly to cover tax withholding obligations resulting from RSU vesting.